Clinical Trials · NCT04143945
A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 104
- Start date
- Oct 2019
- Locations
- 1 site, Netherlands
- Primary endpoint
- Intensity of Injection Site Pain